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NK  cells  mediate  spontaneous  killing of tumor-derived  cells,  virus-infected 
cells, and certain normal cells (1,  2).  This type of cytotoxicity does not require 
presensitization  of  the  donor.  For  example,  PBMC  of  individuals  who  are 
seronegative  or  seropositive  for a  given  virus are  equally able  to  lyse targets 
infected with that virus (3). Production of IFN by lymphocytes exposed to virus- 
infected target cells and subsequent stimulation of NK cells by IFN was originally 
proposed as the mechanism by which NK cells preferentially lyse virus-infected 
cells compared with uninfected ones (4). A primary role for IFN was challenged, 
however, by several authors who described a  lack of correlation between mag- 
nitude  of lysis and  amounts  of IFN  detected  in  supernatant  fluids  (5,  6),  an 
almost  normal  capacity of effector cells  from patients  with reduced  ability to 
produce IFN to lyse virus-infected target cells (7), and the inability of anti-IFN 
antibodies when present during the NK assay to prevent lysis of virus-infected 
cells (5, 6). 
The cells responsible for NK activity against normal and tumor-derived target 
cell lines were identified as a  leukocyte subset, distinct from B and T  cells and 
from myelomonocytic cells (2).  This subset expresses the low-affinity Fc receptor 
(FcR) 1 for aggregated IgG (CD16 antigen), recognized by a  series of mAbs (8). 
NK  cells responsible  for lysis of virus-infected target cells  have not been  fully 
identified.  Fitzgerald  et  al.  (9)  reported  that  the  NK  cells  able  to  lyse  HSV- 
infected targets differed from those that lysed K562 cells, as treatment of PBMC 
with  an  mAb  to  HLA-DR  plus  C  reduced  their  ability  to  kill  HSV-infected 
fibroblasts,  but  not  K562  cells.  These  authors  concluded  that  these  NK  cell 
subsets could be  distinguished on  the basis  of surface expression  of HLA-DR 
antigen.  However,  few if any resting NK (CD16+)  cells in  healthy donors are 
HLA-DR  + (10,  1 1),  raising the possibility that in the experiments of Fitzgerald 
et a]. (9), a  HLA-DR  +, non-NK cell population was depleted. 
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In this study we investigated the role of HLA-DR  + cells in NK activity against 
virus-infected  cells,  using  as  targets  (cytomegalovirus-infected) CMV-infected 
fibroblasts, which were previously shown to be susceptible to NK cell-mediated 
lysis (3,  12,  13).  Our results  indicate that  treatment of PBMC  with anti-HLA- 
DR antibody plus C reduces cytotoxic activity against CMV-infected targets, but 
not against  K562,  by depleting  an  HLA-DR+,CD16 -  population  that  contains 
accessory cells that stimulate CD 16 + NK cells to exert cytotoxic activity against 
CMV-infected targets. A  factor that stimulates NK cytotoxic activity is produced 
when  such  HLA-DR  +  cells  are  cocultivated  with  CMV-infected  targets.  This 
factor is identified as IFN-oc 
Materials and Methods 
Media  and Reagents.  RPMI-1640  medium  (Gibco Laboratories, Grand  Island,  NY) 
was supplemented with 2 mM glutamine,  125 IU/mi penicillin, 6.25 #g/ml gentamicin, 
and  10%  heat-inactivated FCS  (Hyclone Laboratories,  Logan,  UT).  Eagle's  modified 
MEM (Gibco Laboratories) was supplemented with 7.5% FCS,  2% vitamins, and 2 mM 
glutamine, rIFN-c~ with antiviral activity of 5.2 +  3.4 X 10  ~ IU/ml was kindly provided 
by Patrick Trown, Hoffman-LaRoche Inc., Nutley, NJ. 
Monoclonal  and Polyclonal Antibodies.  mAb anti-Leu-11 b (clone G022, IgM; reference 
8), which recognizes the low-affinity Fc receptor (CD16 antigen) on a subpopulation of 
granular lymphocytes known to contain most of the NK activity against K562 cells and 
on neutrophils, was purchased from Becton Dickinson & Co., Mountain View,  CA.  The 
preparation of antibody B33.1 (IgG2a, reference 14), which recognizes a nonpolymorphic 
determinant of the HLA-DR molecule, anti-monocyte (CD14 antigen) antibodies B52.1 
(IgM, reference 15), B13.4 (IgM, reference 16), anti-pan T  cell (CD5 antigen) antibody 
B36.1  (IgG2b, reference 14) was previously described (14,  15). The antigen defined by 
OKM 1 mAb is present on monocytes and granulocytes (17). Anti-B cell BA1  (18) was 
purchased from Hybritech, Inc. (San Diego, CA).  Antibody B133.3 (IgG1), which neu- 
tralizes human  IFN-3,  but  not  IFN-a  or -13, was  previously described (19).  The tissue 
culture supernatant fluid used in the present study had a  neutralizing titer of 32,400 
U/ml.  A  sheep antiserum against  human  IFN-a (105 neutralizing U/ml) was  obtained 
from Interferon Sciences Inc. (New Brunswick, NJ). A calf antiserum to human IFN-/3 (2 
x  105 neutralizing U/ml) was obtained from ICN Radiochemicals, Irvine, CA. 
Preparation of Target Cells.  CMV-infected (CMV-FS4) and uninfected (FS4) fibroblasts 
were prepared as previously described (3). Briefly, human embryonic foreskin fibroblasts 
(FS4 strain,  National Institutes of Allergy and Infectious Diseases,  Bethesda, MD) were 
maintained in MEM and used at passage level 12-22. Monolayers of FS4 in 75-cm  2 flasks 
were  infected  with  human  cytomegalovirus strain  AD-169  (American  Type  Culture 
Collection, Rockville, MD)  at a  multiplicity of infection of ~0.1.  When  ~90%  of cells 
exhibited cytopathic effect (after 5-7 d), the monolayers were trypsinized, washed, and 
suspended in MEM containing 10% DMSO. Aliquots were kept at -70°C for 12-16 h, 
transferred to the vapor phase of a liquid nitrogen freezer, and kept there until use. K562 
cells,  kindly  provided  by  Drs.  Gertrude  and  Werner  Henle  (Children's  Hospital  of 
Philadelphia), were passaged in RPMI-1640 supplemented with  10%  FCS, and cryopre- 
served as described above. Cell lines and target cells were routinely tested for mycoplasma 
and were found to be negative. 
Preparation  of Effector  Cells.  PBMC  of healthy  randomly  selected  seropositive  or 
seronegative adult donors were separated by Ficoll-Hypaque density gradient centrifuga- 
tion.  Adherent  cells  were  removed by  incubation  on  FCS-coated  plastic  petri  dishes 
(Corning Glass Works, Corning, NY) for 1 h at 37°C as previously described by others 
(20).  Nonadherent PBMC were used in all experiments except those indicated, in which 
adherent cells, obtained by scraping the plastic dishes after extensive washing with PBS, 
were  used.  Cell  viability of adherent and  nonadherent populations as  determined by 
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Antibody Plus C-mediated Lysis.  Antibodies were added to  5  x  106  PBMC  in a  total 
volume of 1 ml of RPMI  1640 containing 10% FCS. Final dilutions based on preliminary 
experiments were: anti-Leu-11 b,  1 #g/ml; B33.1/ascitic fluid, 1:100;  B52.1/ascitic fluid, 
1:200; B13.4/ascitic fluid, 1:200; OKM 1/culture supernatant,  1:2; B36.1/culture super- 
natant,  1:4; BA 1,  1 #g/ml. In selected experiments more than one antibody was added to 
PBMC. After a  1 h  incubation at room temperature, cells were centrifuged (100 g for 10 
rain), resuspended in  1 ml of baby rabbit C  (Pel-Freeze Biologicals, Rogers, AZ), diluted 
1:2,  and  incubated  for  1  h  at  room  temperature.  The  cells  were  centrifuged,  the 
supernatant was removed, and treatment with C was repeated. The cells were then washed 
twice and resuspended in RPMI  1640 containing 10%  FCS. Viability was determined by 
trypan blue exclusion. Treatment with C alone had no effect on cell viability and reduced 
spontaneous NK (CMV-FS4) by <15%. 
Detection of Surface Markers by Direct Immunofluorescence.  The proportion of NK, B, T, 
monocytic, and  HLA-DR  +  cells in  the  preparations  treated  with  antibody  and  C  was 
determined  by  immunofluorescence  (flow  cytofluorometry),  as  described  (14).  FITC 
conjugates of the following antibodies were used: CLB (anti-CD16), kindly provided by 
Dr. Tetteroo (Central  Laboratory of the Netherlands, Amsterdam) for the detection of 
NK cells (21); OKT3 (anti-CD3) for detection of T  cells (22); B1  for detection of B cells 
(23); B44.1  (anti-CD 14) for detection of monocytes (15); and B33.1 for detection of HLA- 
DR + cells. PBMC were resuspended in PBS (pH  7.2) containing 2%  FCS and incubated 
with previously determined optimal dilutions of the FITC-conjugated antibodies for 30 
rain at 4°C. The cells were then washed three times and analyzed using a Cytofluorograf 
System 50 HH connected to a 2150 data handling system (Ortho Diagnostic Systems Inc., 
Westwood,  MA).  Cells were  considered positive when  their  fluorescence  intensity ex- 
ceeded the  threshold at  which  99%  of unstained  cells had  lower fluorescence intensity 
(14). 
Nonspecific Esterase Staining.  Nonspecific esterase stains were done as previously de- 
scribed (24). 
Irradiation  of Effector Cells.  Aliquots of PBMC,  Leu-1 lb-, or  HLA-DR-  cells (5  x 
10~/ml) were exposed at room temperature to 50 Gy from a cesium-l.37 source (Gammator 
M; Isomedix Inc., Parsippany, NJ). Control aliquots kept at room temperature were not 
irradiated. All cells were assayed within  1 h after irradiation. 
Cocultivation of PBMC, Leu-1 Ib-, and HLA-DR- Cells with Uninfected and CMV-infected 
Fibroblasts.  PBMC,  Leu-1 lb-, or  HLA-DR- cells were  cocultured with  FS4 or  CMV- 
FS4 for  18 h at 37°C at an E/T ratio of 50:1  (2.5 X  I0 6 effector cells and 5 x  104 target 
cells per ml) in a total volume of 3 ml in 5-ml plastic tubes. Cell-free supernatant fluid was 
collected after  centrifugation  (100  g  for  10  rain) and  kept  at  -70°C  for  subsequent 
determination of antiviral activity and ability to stimulate HLA-DR- cells to mediate NK 
(CMV-FS4). 
IFN Titration.  A  previously described cytopathic effect inhibition assay was used to 
quantitate antiviral activity (25). Briefly, twofold serial dilutions of samples were incubated 
with  WISH  cells  in  microtiter  plates  for  24  h  at  37°C.  The  monolayers  were  then 
challenged  with  vesicular stomatitis  virus  (2,500  PFC/well).  After an  additional  24-h 
incubation at  37°C,  the monolayers were stained with  0.5%  crystal violet/70% methyl 
alcohol. Each assay included cell and  virus controls. Titers were calculated in IU based 
on results obtained with the National Institutes of Health reference standards for IFN-a 
(G-023-901-527) and IFN-3, (Gg23-901-530). 
NK Celt Assays.  NK cell assays against K562 cells and uninfected and CMV-infected 
fibroblasts were performed as described (3). Cryopreserved targets were thawed rapidly, 
washed twice, and resuspended in 0.2  ml of HBSS.  50 uCi of Na251CrO4  (407  mCi/mg 
spe act;  ICN  Radiochemicals,  Irvine, CA)  were added  per  1-2  x  106  cells.  After  1  h 
incubation at 37 °  C  in 5% CO2 with gentle shaking every 15 min, the cells were washed 
four times and then resuspended in RPMI  1640 with  10%  FCS at a concentration of 5 x 
104 cells/ml. 5 x  103 target cells in 0.1 ml of RPMI 1640 containing 10% FCS and various 
concentrations of effector cells in 0. l-hal aliquots were added to round-bottomed micro- 
titer  wells  (Linbro  Chemical  Co.,  Hamden,  CT)  to  yield the  desired  E/T  ratios.  All BANDYOPADHYAY ET  AL.  183 
TABLE  I 
Cytotoxicity Mediated by PBMC, Leu-1 Ib-, and HLA-DR- Cells Against Various Target Cells 
Donor 
Target cell FS4  Target cell CMV-FS4  Target cell K562 
Leu-I lb- + 
PBMC  Leu-I lb-*  HLA-DR-*  PBMC  Leu-1 lb-  HLA-DR-  HLA-DR-*  PBMC  Leu-llb-  HLA-DR- 
1  0.0  0.0  0.0  20.2  6.1  4.1  ND  38.3  5.7  28.0 
2  11.8  0.6  10.6  31.1  11,8  3.8  ND  70.0  6.6  66.3 
3  0.0  0.0  0.0  31.2  4.3  4.0  ND  66.2  2.3  64.5 
4  10.8  4.0  13.5  35.0  10,5  2.6  ND  48.6  3.6  49.2 
5  ND  ND  ND  30.1  3,4  0.0  22.2  ND  ND  ND 
6  7.0  0.0  7.1  27.2  4.0  2.8  28.6  50.5  0.0  54.3 
7  ND  ND  ND  45.3  2.3  0,0  42.3  ND  ND  ND 
8  ND  ND  ND  28.5  7.4  2.8  23.0  ND  ND  ND 
1-8  !  5.9±5.7  0.9±1.71  6.2±6.1  31.1±7.1  6.2±3.44  2.5±1.6  ~  29.0±9.3  54.7±13.1  3.6±2.64  52.5±15.4 
Cytotoxicity  (percent SlCr release) was assayed  as described in Materials and Methods. E/T ratio, 50:1. 
* Leu-I 1  b- and HLA-DR- cells were prepared as described in Materials and Methods. 
* Equal numbers of Leuq lb- and HLA-DR- cells were mixed and added to assays. 
! Mean _+ SD, 
I p <  0.05 compared with results with PBMC, paired t test (only data for donors 2.4, and 6 were included in the analysis). 
i p <  0,O01 compared with results with PBMC, paired t test. 
determinations were done in triplicate. Plates were centrifuged at  100 g for 6 rain and 
then incubated for 18 h at 37 °C in 5% CO2. After incubation, 0.1  ml of supernatant was 
collected from each well without disturbing the cell pellet and counted in a gamma counter 
(4000; Beckman Instruments,  Inc., Fullerton, CA).  In selected experiments, additional 
50 ~tl aliquots of supernatant were harvested from triplicate wells, pooled, and kept at 
-70°C  for subsequent determinations of antiviral activity. The percent of 51Cr release 
was calculated using the formula: percent 5tCr release =  100  x  [(cpm experimental) - 
(cpm spontaneous)]/[(cpm total) -  (cpm spontaneous)] where spontaneous release was that 
obtained from target cells incubated with medium alone and total release was that obtained 
from target cells incubated with 1% Triton X-100 detergent. In 18 h assays, spontaneous 
release from uninfected and CMV-infected targets never exceeded 35% of total release 
while spontaneous release from K562 cells never exceeded 30%. 
Statistical Analysis.  The two-tailed paired t test was used for all analyses. 
Results 
Cells Participating in NK Cytotoxicity  against Different Targets.  Uninfected FS4 
cells were lysed at a  low level of magnitude  by PBMC  from some, but not all, 
healthy donors, whereas CMV-infected FS4 cells were efficiently lysed by PBMC 
of all  donors  tested  (Table  I).  To  identify the  cells  participating  in  NK  cell- 
mediated cytotoxicity, the surface markers of the effector cell populations active 
against  uninfected  fibroblasts,  CMV-infected  fibroblasts,  and  a  tumor-derived 
target  cell  line  (K562)  were  compared  using  the  anti-CD16  (low-affinity FcR) 
antibody  anti-Leu-1 lb  and  the  anti-HLA-DR  antibody  B33.1.  Treatment  of 
PBMC with anti-Leu-11 b plus C significantly reduced NK(CMV-FS4), NK(FS4), 
and  NK(K562)  (Table  I  and  Fig.  1).  In  contrast,  treatment  of  PBMC  with 
antibody B33.1  plus C  significantly reduced NK(CMV-FS4), but not NK(K562) 
or  NK(FS4).  Since  the  effect was  consistent  at  all  E/T  ratios  tested  (Fig.  1), 
subsequent experiments were done using E/T ratios of 50:1. 
To  define  further  the  HLA-DR +  cells  required  for  NK(CMV-FS4),  PBMC 
were treated with mAbs specific for cells of different lineages plus C, as described 
in  Materials  and  Methods.  Depletion  of T  cells  to  <1.8%,  as  determined  by 184  COOPERATION  OF  HLA-DR  ÷  AND  NATURAL  KILLER  CELLS 
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FIGURE  1.  Effect of depletion  of CDI6(Leu-I lb)* and HLA-DR  + cells on  NK (CMV-FS4) 
(left) and NK(K562) (right).  PBMC were treated wtih C  (O), anti-Leu-1 lb +  C (&), or B33.1  + 
C (A) as described in Materials and Methods, washed twice, and tested at different E/T ratios 
for NK activity. Results shown are representative of four similar experiments. 
immunofluorescence (flow cytometry), had no effect on  NK(CMV-FS4)  (Table 
II,  Exp.  1).  Similarly, depletion  of either  B  cells  or  monocytes to  <0.1%,  as 
determined by flow cytometry and nonspecific esterase staining respectively, or 
of both B cells and monocytes had no effect on NK(CMV-FS4) (Table II, Exp. 
2).  In another approach,  monocytes and B cells were depleted from  Leu-1 lb- 
cells with specific mAbs and C.  When such populations depleted of monocytes 
(<0.5% esterase-positive), B cells, and NK cells were mixed with HLA-DR- cells 
at  a  ratio  of  1:1  and  tested  for  NK(CMV-FS4),  activity  was  largely  restored 
(Table II, Exp. 3).  Finally, graded numbers of plastic dish adherent cells (>95% 
nonspecific esterase-positive)  were added  to  HLA-DR-  cells and  the  mixtures 
tested for NK(CMV-FS4)  activity. While addition of as  few as  2.5  X  104  Leu- 
1 lb- cells to HLA-DR- cells largely reconstituted NK(CMV-FS4), addition of as 
many  as  2.5  x  105  adherent  cells  to  HLA-DR-  cells  failed  to  reconstitute 
NK(CMV-FS4) (Table II, Exp. 4). Thus, these data indicate that HLA-DR  + cells 
required  for  NK(CMV-FS4)  were  neither B  or T  lymphocytes, nor were  they 
monocytes. 
Since NK(CMV-FS4) activity was largely restored (Tables I and II) when Leu- 
1 lb- and HLA-DR- cell populations of individual donors were mixed, treatment 
with anti-Leu-1 l b or anti-HLA-DR plus C appeared to suppress cytotoxicity by 
acting on two different cell populations, one Leu-1 lb-, HLA-DR  + and the other 
Leu-1 lb+,HLA-DR  -. 
Leu-11b- and  HLA-DR- cells were next combined at additional E/T ratios. 
NK(CMV-FS4)  and  NK(K562)  rose  as  the  percentage  of HLA-DR-  cells  was 
increased  from  0  to  80%  and  0  to  50%,  respectively (Fig.  2).  There  was  no 
further increase in  NK activity against the two targets after the percentage  of 
HLA-DR- cells reached 97%. Maximal NK(K562) was still observed with  100% 
HLA-DR-  cells.  NK(CMV-FS4)  was  not  mediated  by  HLA-DR-  cells  in  the 
absence of Leu-I lb- cells, but 3% Leu-1 lb- cells were sufficient to reconstitute 
maximal  NK(CMV-FS4).  Because <20%  of the  cells  in  Leul lb-  preparations 
were  HLA-DR  +  (not  shown),  <0.6%  HLA-DR  +  cells  were  required  to  fully BANDYOPADHYAY  ET  AL.  185 
TABLE  II 
Characterization of Cells Contributing to NK Against CMV-FS4 
Exp.  Effector cells in NK assays 
Percent SZCr release from 
CMV-FS4 
Donor 1  Donor 2 
PBMC 
B36.1- 
14.2  26.7 
11.0  24.0 
2* 
3* 
4 j 
PBMC 
BA1- 
B52.1- 
B13.4- 
BAl-,B52.1-,BI  3.4- 
PBMC 
Leu-1 Ib- 
Leu-1 lb-,BA I-,B52.1-,B13.4-,OKM1- 
HLA-DR- 
Leu-1 lb- + HLA-DR- 
Leu- 11 b-,BA 1-,B52.1-,B13.4-,OKM  I- + HLA-DR- 
PBMC 
HLA-DR- 
Leu-1 Ib- 
HLA-DR- + Leu-1 lb- (2.5 x  104) 
HLA-DR- + Leu-1 lb- (5 x  104) 
HLA-DR- + Leu-I lb- (2.5 x  105) 
Adherent cells 
HLA-DR- + adherent cells (2.5 x  104) 
HLA-DR- + adherent cells (5 x  104) 
HLA-DR- + adherent cells (2.5 x  10  s) 
23.4  23.7 
22.7  25.8 
23.2  22.6 
20.4  39.5 
20.9  29.6 
19.3  ND 
7.9  ND 
6.7  ND 
1.4  ND 
16.5  ND 
18.2  ND 
31.5  25.7 
4.5  1.0 
7.8  6.1 
36.3  17.7 
36.6  23.9 
34.0  21.4 
<1.0  1.7 
2.9  3.9 
6.4  4.9 
5.7  ND 
* PBMC or PBMC depleted of subsets of cells as described in Materials and Methods were added to 
CMV-FS4 at an E/T ratio of 50:1. 
* Final E/T ratios were 50:1 for all effector cell populations  including mixtures.  Mixtures consisted 
of equal numbers of depleted cell populations. 
§ Graded numbers (as indicated in parentheses)  of Leu-1 lb- cells or plastic dish adherent cells and 
2.5 x  105 HLA-DR- cells were added to CMV-FS4. 
reconstitute  the  ability  of  HLA-DR-  cells  to  mediate  NK(CMV-FS4).  These 
results suggested that CD16(Leu 1 1  b)  + cells were the effector cytotoxic cells for 
both  NK(K562)  and  NK(CMV-FS4),  while  small  numbers  of HLA-DR +  cells 
provided an accessory function for NK(CMV-FS4). 
Effect  of Irradiation  on  the Ability  of PBMC,  Leu-llb-,  and HLA-DR-  Cells to 
Mediate NK(CMV-FS4).  Our previous experiments suggested that Leu-1 lb  + and 
HLA-DR ÷ cells have different functions in mediating NK(CMV-FS4). We there- 
fore  determined  whether  these  functions were equally sensitive to  irradiation, 
which  has  been  reported  to  reduce  NK(K562)  (26,  27).  PBMC-mediated 
NK(CMV-FS4) was  markedly reduced after irradiation with  50  Gy (Table III). 
Mixtures  of irradiated  HLA-DR-  cells  plus  nonirradiated Leu-1 lb-  cells  had 
little or no N K(CMV-FS4) activity, whereas mixtures of irradiated Leu-1 1  b- cells 
plus nonirradiated HLA-DR-  cells mediated levels of NK(CMV-FS4) similar to 
those of mixtures of nonirradiated cells (Table III). 186  COOPERATION  OF  HLA-DR  + AND  NATURAL  KILLER  CELLS 
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FIGURE 2.  Effect of combining CD16(Leu-1  lb)- and HLA-DR- cells on NK activity against 
CMV-FS4 (0) and K562 (A). CD16(Leu-1  lb)- and HLA-DR- cells, prepared as in Fig. 1 were 
mixed at varying ratios and added to targets at an E/T ratio of 50:1. 
TABLE  llI 
Effect of Irradiation of PBMC, Leu-1 lb-, and HLA-DR- Cells on 
NK Cytotoxicity Against CMV-FS4 Target Cells 
Percent 5~Cr  Effector cells*  release 
PBMC  45.3 
PBMC (irradiated)  ~;  10.4 
Leu-I lb-  2.3 
HLA-DR-  0.0 
Leu-1 lb- + HLA-DR  -i  42.3 
Leu-1 l b- (irradiated) + HLA-DR- (irradiated)  §  3.3 
Leu-1 lb- (irradiated) + HLA-DR  -6  33.1 
Leu-1 lb- + HLA-DR- (irradiated)  ~  7.2 
* E/T, 50:1. 
* PBMC, Leu-1 lb-, and HLA-DR- cells were irradiated with 50 Gy. 
Equal numbers of Leu-1 lb- and HLA-DR- ceils were added to the NK 
assay. 
Supernatant  Fluids from  Cocultures  of PBMC or Leu-11b-  Cells with CMV-FS4 
Contain  IFN-a  Which  Stimulates  HLA-DR-  Cells  to  Mediate  NK(CMV-FS4)  and 
NK(FS4).  Since  HLA-DR-  cells  mediated  NK(CMV-FS4)  in  the  presence  of 
small  numbers  of Leu-1 lb-  cells (3%),  we  tested  the  possibility that  Leu-1 lb- 
cells might secrete soluble factor(s) that stimulate NK cells present in HLA-DR- 
populations  to  mediate  NK(CMV-FS4).  PBMC,  Leu-1 lb-,  or  HLA-DR-  cells 
were cocultured with FS4 or CMV-FS4 at a  ratio of 50:1  for  18 h  at 37 °  C. Cell- 
free  supernatants  were  then  collected  and  added  at  a  final  dilution  of  1:2  in 
cytotoxicity assays using HLA-DR-  or Leu-1 1 b- cells as effectors. The magnitude 
of  NK(CMV-FS4)  mediated  by  Leu-1 lb-  effector  cells  remained  low  despite 
addition of supernatants  generated  by cocuhuring  PBMC,  Leu-1 lb-,  or  HLA- 
DR-  cells  with  CMV-FS4  (results  not  shown).  In  contrast,  when  supernatants 
generated  by cocuhuring  PBMC  or  Leu-1 lb-  cells with  CMV-FS4  were  added 
to  HLA-DR-  cells, NK(CMV-FS4)  activity was completely restored (Table  IV). 
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TABLE  IV 
Effect of Supernatants Generated by Coculturing PBMC, Leu-11b-, or HLA-DR- Cells with 
Uninfected or CMV-infected Targets on Cytotoxicity Mediated by Fresh HLA-DR- 
Cells Against CMV-FS4 
Antiviral activ-  Percent 51Cr release 
Effector cells*  Supernatant added to  ity (IU/ml) 
NK assay*  of the 
supernatant§  Exp.  1  Exp. 2 
PBMC  None  --  44.6  48.6 
HLA-DR-  None  --  8.4  18.6 
HLA-DR-  PBMC +  FS4  <20  5.6  11.5 
HLA-DR-  PBMC +  CMV-FS4  2,406  51.3  51.6 
HLA-DR-  Leu-1 lb- +  CMV-FS4  2,406  58.2  46.8 
HLA-DR-  HLA-DR- +  CMV-FS4  <20  5.8  ND 
*  PBMC and HLA-DR- cells were prepared as described in Materials and Methods. E/T, 50:1. 
* The  leukocyte-target  cell  combination  used  to generate  each  supernatant  is shown.  Leukocytes 
were cocuhivated with target cells at a ratio of 50:1 for 18 h at 37 ° C as described in Materials and 
Methods. Aliquots of 100 #1 of supernatants were added to NK assays to give final concentrations 
of 1:2. 
Antiviral activity of supernatants was measured as described in Materials and Methods. 
TABLE  V 
Effect of PBMC-CMV-FS4 Supernatant and rlFN-a on NK activity against FS4 and 
CMV-FS4 
Exp.  Donors  Effector cells*  Additive to 
(n)  medium 
Percent S'Cr release from: 
FS4  CMV-FS4 
1'  5 
21  2 
PBMC  none  3.6 +  4.1 ~  30.4 +  15.2 
HLA-DR-  none  4.5 _  3.3  7.7 _  6.6 
HLA-DR-  supernatant  21.5 -  8.4  39.7 _+  11.6 
PBMC  none  4.0 -+ 5.6  19.3 --+ 9.9 
PBMC  supernatant  37.5 _+ 2.2  52.8 +  10.4 
PBMC  rIFN-a  40.4 -+ 3.9  56.6 -+ 13.4 
HLA-DR-  none  0.0 -+ 0.0  5.5 +  7.7 
HLA-DR-  supernatant  27.3 _  0.5  43.5 _  4.9 
HLA-DR-  rIFN-a  20.8 -  1.1  37.2 -  9.3 
* E/T, 50:1. 
* 100  #l  of the supernatant generated  as described  in  Materials and 
assays to give final concentrations of 1:2. 
Mean +  SD. 
II  Effector  cells  were  incubated  with  supernatant  (1:4  final  dilution) 
IU/ml) for  18 h, washed twice, and added to the NK assays. 
Methods were  added  to  NK 
or  recombinant  IFN-c~  (500 
HLA-DR- cells with CMV-FS4  or PBMC  with  FS4  were added to  HLA-DR- 
cells (Table IV). In the presence of PBMC-CMV-FS4 supenatant, HLA-DR- cells 
also mediated NK(FS4), although the magnitude of lysis was considerably lower 
than  that  of NK(CMV-FS4)  (Table  V,  Exp.  1).  When  HLA-DR-  cells  were 
pretreated with PBMC-CMV-FS4 supernatant or rIFN-a for 18 h, washed, and 
then tested for NK activity, lysis of both FS4 and CMV-FS4 targets was increased, 
although  the  magnitude  of NK(FS4)  was  lower  than  that  of NK(CMV-FS4) 
(Table V, Exp. 2). 
When  aliquots  of serial,  twofold dilutions  of the supernatant  generated by 188  COOPERATION  OF  HLA-DR +  AND  NATURAL  KILLER  CELLS 
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Dilution of supernatant 
FIGURE  3,  Effect of dilution of the supernatant generated by coculturing PBMC with CMV- 
FS4 on  NK activity mediated by HLA-DR-  cells against CMV-FS4. The generation  of the 
supernatant and depletion of HLA-DR + cells were done as described in Materials and Methods. 
100-~1  aliquots  of serial,  twofold  dilutions  of the  supernatant  were  added  to  NK  assays 
containing HLA-DR- cells as effectors and CMV-FS4 as targets. The E/T ratio was 50:1.51Cr 
release was 4% with HLA-DR- cells alone and 24% with PBMC. 
coculturing PBMC with CMV-FS4 were added to assays,  a  dose-response rela- 
tionship was obtained with respect to HLA-DR--mediated NK(CMV-FS4) (Fig. 
3). 
Supernatants that restored NK(CMV-FS4) contained >2,000  IU/ml of anti- 
viral activity, whereas supernatants unable to restore NK activity contained <20 
IU/ml of IFN (Table IV). We investigated whether IFN in the supernatant was 
responsible for stimulating HLA-DR- cells to mediate NK(CMV-FS4). When the 
IFN-containing supernatant was  diluted  1:4  and  incubated with antiserum  to 
human  IFH-a  sufficient to  neutralize  its  antiviral  activity,  the  ability of the 
supernatant to stimulate HLA-DR- cells to mediate NK(CMV-FS4) (Table VI) 
and NK(FS4) (not shown) was abolished. In contrast, incubation of the superna- 
tant with antibodies to human ]FN-/3 or 3' sufficient to neutralize 2,000  IU  of 
IFN-8 or %  respectively, had no effect on either the ability of the supernatant 
to restore NK(CMV-FS4) by HLA-DR- cells or its antiviral activity (Table VI). 
Effect  of Anti-lFN-a  on  PBMC-mediated  NK(CMV-FS4).  Since  supernatants 
containing IFN-c~ stimulated HLA-DR- cells to mediate NK(CMV-FS4), experi- 
ments were done to determine whether IFN-~ also contributed to  NK(CMV- 
FS4) mediated by PBMC. Antibody to IFN-~ was added to PBMC in microtiter 
wells  before  the  addition  of 5~Cr-labeled  CMV-FS4.  Addition of amounts of 
antibody sufficient to completely neutralize antiviral activity in supernatants did 
not affect the magnitude of NK(CMV-FS4) (Table VII). 
Discussion 
Resting peripheral blood NK cells  from healthy donors do not express HLA- 
DR  antigens;  however,  HLA-DR antigen expression  is  observed  on  NK  cells 
induced to proliferate in vitro (10,  1 1) and on activated NK cells in peripheral 
blood of patients. NK cells are spontaneously cytotoxic, but their activity can be 
enhanced severalfold by various cytokines, e.g., IFN and IL-2 (28,  29).  These BANDYOPADHYAY  ET  AL. 
TABLE  VI 
Effect of Anti-lFN Antibodies on the Ability of PBMC-CMV-FS4 Supernatant to 
Stimulate NK Activity of HLA-DR- Cells 
189 
Antiviral ac- 
Supernatant  Treatment of  tivity (IU/ml)  Percent  51Cr release 
Effector cells*  added to NK  supernatant*  in supernatant  from 
assay  after treat-  CMV-FS4 
ment  0 
PBMC  -  -  -  16.8 
HLA-DR-  -  -  -  5.6 
HLA-DR-  +  medium alone  1203.2  24.6 
HLA-DR-  +  anti-IFN-a  <20.0  5.9 
HLA-DR-  +  anti-IFN-fl  1504.2  24.7 
HLA-DR-  +  anti-IFN-7  1593.6  24.1 
PBMC-CMV-FS4 supernatant was generated as described in Materials and Methods. 
* PBMC and  HLA°DR- cells were obtained as described in  Materials and  Methods. 
E/T, 50:1. 
* ~2,000  neutralizing units  of anti-IFN-a,  anti-IFN-fl, anti-IFN-3,, or medium  alone 
were  incubated  for  1  h  at  room  temperature  with  equal  volumes of supernatant 
diluted 1:4. Aliquots of 100 #1 of each mixture were added to NK assays to give final 
dilutions of 1:2 (1 : 16 of original supernatant). 
§ Antiviral activity was determined as described in Materials and Methods. 
TABLE  VII 
Effect of anti-lFN-a Antibody on Cytotoxic Activity Mediated by PBMC Against 
CMV-FS4 and on IFN Production in the Cytotoxic Assay 
Exp. 
Percent ~Cr release from CMV- 
FS4 in the presence of:* 
Antiviral activity (IU/ml) of 
supernatants generated in the 
presence of:* 
Medium  Anti-IFN-a  Medium  Anti-IFN-a 
1  37.0  33.6  600  <20 
2  31.6  27.3  1,200  <20 
3  41.2  30.2  246  <15 
4  29.6  28.5  1,900  <15 
5  26.1  23.9  300  <20 
1-50  33.1  _  6.0  28.7 _  3.6  849 +  699  -- 
E/T, 50:1. 
* I00  #1  of anti-IFN-a  (-2,500  IFN-a  neutralizing  units)  or  medium  as  added  to 
microtiter plate wells before addition of effectors and target cells. 
* Antiviral activity was determined as described in Materials and Methods. 
0 Mean _  SD. 
activated  NK  cells lyse NK-sensitive target  cells with increased  efficiency and can 
also  lyse  target  cells that  are  poorly  sensitive  to  the cytotoxic  effect of nonacti- 
vated  NK  cells. 
In  the  present  study  we  showed  that  NK  cell-mediated  cytotoxicity  against 
CMV-infected  cells,  unlike  cytotoxicity  against  tumor-derived  or  normal  target 
cells,  depends  on  cooperation  between  two  phenotypically  distinct  cell  popula- 
tions.  NK(K562)  and  NK(FS4),  as expected  (8),  were  abrogated  by treatment  of 
PBMC  with  anti-CD16  (Leu-I Ib)  antibody  plus  C,  but  not  by  anti-HLA-DR 
antibody  plus  C.  Treatment  of  PBMC  with  either  anti-HLA-DR  or  anti-CD16 190  COOPERATION  OF  HLA-DR ÷  AND  NATURAL  KILLER  CELLS 
(Leu-1 lb)  antibody plus  C  reduced  NK(CMV-FS4)  to very low levels.  Experi- 
ments  in  which  mixtures  of Leu-1 lb-  and  HLA-DR-  cells  mediated as  much 
NK(CMV-FS4)  activity as  PBMC  treated  with  C  alone  indicated  that  PBMC- 
mediated  lysis of CMV-FS4  requires  both  CD16+,HLA-DR  -  cells  and  HLA- 
DR+,CD16 -  cells. When cell populations containing different ratios of the two 
cell types were tested for NK(CMV-FS4) activity, cytotoxicity was proportional 
to the number of H LA-DR- cells added, whereas <3% CD 16- cells (correspond- 
ing to <0.6% HLA-DR  + cells) were required for maximal NK(CMV-FS4) activity. 
These results indicate that the limiting cells in lysis of CMV-FS4 are HLA-DR- 
and  suggest  that  HLA-DR  ÷ cells  play an  accessory role  and  stimulate CD16 + 
effector cells to mediate NK(CMV-FS4) activity. Distinct roles for the HLA-DR  + 
and  CD16 + populations  were  also  suggested  by  the  results  of the  irradiation 
experiments. The cytotoxic function of HLA-DR- cells was abolished by expo- 
sure to 50 Gy, as expected based on previously published data (26, 27), whereas 
the accessory  function of Leu-1 lb-  cells was radioresistant.  Borysiewicz et al. 
(13)  have shown that  Leu-11 + cells purified by cell sorting can lyse CMV-FS4. 
These  results  appear  to  contrast  with  those  of  our  depletion  experiments. 
However, this discrepancy might be explained by efficient enrichment of spon- 
taneously  cytotoxic  cells  in  the  positively  selected  Leu-ll +  population  and, 
possibly, contamination of the Leu-11 + population with small numbers of HLA- 
DR  + cells, which we  have shown to be sufficient, at levels as low as 0.6%,  for 
optimal NK(CMV-FS4) activity. Furthermore,  since we have observed (unpub- 
lished  results)  that  treatment  of PBMC  with  the  anti-CD16  B73.1  antibody 
enhances cytotoxic activity of NK cells against various relatively NK-insensitive 
target cells, the results of positive selection experiments must be interpreted with 
caution. 
The possibility that HLA-DR  + cells might produce a  soluble mediator that in 
turn stimulated CD 16(Leu-1 ! b)  + cells to become cytotoxic was investigated. Cell- 
free supernatants of PBMC or Leu-1 lb- cells incubated with CMV-FS4 targets 
stimulated HLA-DR- cells to mediate NK(FS4) and  NK(CMV-FS4) activity. In 
contrast, supernatants of HLA-DR- cells incubated with CMV-FS4 targets could 
not  do  so.  A  dose-response  relationship  was  observed  between  dilutions  of 
supernatants able to stimulate HLA-DR- cells and the magnitude of NK(CMV- 
FS4) activity, and  maximal stimulation of cytotoxicity was observed when the 
supernatant was added at the final concentration of >_3%. 
Supernatants that stimulated HLA-DR- cells contained antiviral activity, and 
when anti-IFN-oe antibody was added in sufficient quantities to neutralize this 
activity, the ability of the supernatants  to stimulate cytotoxic activity of HLA- 
DR-  cells  was  abolished.  In  contrast,  addition  of anti-IFN-/3  or  anti-IFN-3, 
antibodies affected neither the antiviral activity of supernatants nor their ability 
to stimulate NK(CMV-FS4) activity. These data indicate that IFN-c~ present in 
the supernatants was responsible  for stimulating CD16+HLA-DR -  cells to me- 
diate NK(FS4) and NK(CMV-FS4).  Negative selection studies indicated that the 
HLA-DR  + cells that contributed to NK(CMV-FS4) activity did not have surface 
markers  of B  cells,  T  cells,  or  monocytes.  It  was  of particular  importance  to 
determine whether monocytes might contribute to NK(CMV-FS4) since mono- 
cytes  are  both  HLA-DR  +  and  have  been  reported  to  produce  IFN-c~  when BANDYOPADHYAY ET  AL.  191 
stimulated with certain  viruses.  However,  PBMC  depleted of monocytes with 
three mAbs plus C and containing <0.5% nonspecific esterase-positive cells could 
fully reconstitute NK(CMV-FS4), suggesting that monocytes were not necessary 
for reconstitution.  Furthermore, purified adherent cells that contained >95% 
nonspecific esterase-positive cells  could not  reconstitute  NK(CMV-FS4)  when 
added  to  HLA-DR-  cells,  and  supernatants  of these  assays  did  not  contain 
detectable IFN-c~. These findings strongly suggest that the HLA-DR  + cells, which 
provide accessory function to Leu-11 b + NK cells, are not monocytes. The HLA- 
DR  + cells that provide the accessory function for NK(CMV-FS4) activity may be 
identical to the HLA-DR  + peripheral blood leukocyte subset described by Perus- 
sia et al.  (30,  31) as  the major producer of IFN-a after exposure of PBMC to 
viruses or to virus-infected targets. This cell type has not yet been completely 
characterized; it represents  a  small  proportion  of nonadherent PBMC  (<1%) 
(31),  and has phenotypic and density characteristics similar to those of reported 
antigen-presenting cells, cells providing accessory functions for B cell stimulation 
(32),  and cells stimulating autologous mixed lymphocyte reactions (33). 
Our results show that IFN-~, which is able  to stimulate CD16 ÷ cells to lyse 
CMV-FS4, is produced during interaction of PBMC with CMV-FS4, and that a 
CD 16-,HLA-DR  + leukocyte subset is required for both production of IFN-a and 
lysis of CMV-FS4.  Moreover our findings indicate that  the  HLA-DR  ÷ IFN-~- 
producing cells are present in excess in PBMC preparations from healthy donors, 
and that IFN-a is produced by HLA-DR  + cells  in contact with CMV-FS4 in a 
much  higher  concentration than  needed  for  optimal  NK(CMV-FS4)  activity. 
These results suggest that the reported lack of correlation between concentra- 
tions of IFN-c~ in cultures and NK lysis of virus-infected target cells (5, 6) cannot 
be considered as evidence against a role for IFN in cytotoxicity activity. For the 
same reason, a  correlation between the ability to PBMC from various types of 
patients to produce IFN-o~ and their ability to lyse virus-infected cells (7) should 
not be  expected;  rather,  lysis of virus-infected cells  should correlate with the 
number and activity of CD16 + cytotoxic cells,  which we have shown to be the 
limiting cells  in  the  cytotoxic reaction.  However, similar to results previously 
reported  by  Fitzgerald et al.  (9)  and  by  Bishop et al.  (5)  with respect  to  NK 
cytotoxicity against HSV-infected target cells, the presence in cytotoxic assays of 
quantities of anti-IFN-c~ antibody sufficient to  neutralize extracellular IFN-c~ 
had no significant effect on NK(CMV-FS4) activity. There are several possible 
explanations for the inability of anti-IFN-~ antibodies to inhibit NK(CMV-FS4) 
when  added  directly to  the  cytotoxicity assay.  HLA-DR  + cells  may release  a 
factor in addition to IFN-c~ that can activate CD16 + NK cells; such a factor might 
not be demonstrable in supernatant fluids either because it is labile or because it 
is  present  at effective concentrations only in  the  intercellular spaces  between 
contiguous cells.  Alternately, HLA-DR  + cells might activate CD16 ÷ cells  by a 
mechanism that requires cellular contact but that also depends on IFN; both the 
antiviral  and  the  cytotoxicity-enhancing effect of IFN  can  be  transferred  by 
direct cellular contact, with no requirement for extracellular IFN (34). However, 
the inability of anti-IFN antibodies to inhibit NK(CMV-FS4) does not exclude 
the possibility that  the  increased sensitivity of the  infected target cells  is  due 
exclusively to the NK-enhancing effect of extracellular IFN-~. As discussed, IFN- 192  COOPERATION  OF  HLA-DR  +  AND  NATURAL  KILLER  CELLS 
c~ is present in the supernatant  fluid of cytotoxic assays at concentrations  much 
higher than required for optimal  NK(CMV-FS4) activity; it is possible that high 
concentrations of IFN-a in the intercellular spaces of cell pellets cannot be readily 
inhibited by the amounts of anti-IFN-a antibody used and thus activation of NK 
cells may occur before IFN-a is completely inactivated. 
In conclusion, our data indicate that a subset of CD16-,HLA-DR + leukocytes 
interacts  with  CMV-infected  fibroblasts and  activates  cytotoxic CD16 +,  HLA- 
DR- NK cells by releasing IFN-t~, and possibly also by other mechanisms involving 
either labile soluble factors or cellular contact. These observations might explain 
why increased sensitivity of virus-infected fibroblasts to NK cells cannot be shown 
before 4-6  h  of culture and  is maximal  at  18-24  h.  CMV  infection  may also 
affect the sensitivity of target cells to the cytotoxic signal of NK cells and enhance 
the ability of NK cells to bind to target cells (unpublished data).  However, the 
extent of lysis of CMV-infected target cells seems to be primarily determined by 
the  accessory  HLA-DR  + cells,  which  after  interaction  with  the  virus-infected 
cells, nonspecifically activate cytotoxic NK cells. These activated NK cells lysed 
both  uninfected and  CMV-infected  target  cells, although  in  the  present  study 
the latter were lysed somewhat more efficiently.  In other studies, cells infected 
with murine CMV or with HSV-1 have been shown to be less or equally sensitive 
to lysis, respectively, as compared with uninfected target cells (35, 36). Trinchieri 
et al.  (28) showed that  IFN, shown here to be produced by the HLA-DR  + cells, 
might  contribute  to  the  selective  killing  of virus-infected  cells  by  rendering 
uninfected  cells,  but  not virus-infected  cells,  resistant  to the  lysis  mediated  by 
NK cells.  Bukowski and  Welsh (37) recently reported that  the inability of IFN 
to protect virus-infected cells against lysis by NK cells correlates with NK cell- 
mediated antiviral effect in vivo. Such data strongly support the hypothesis that, 
in  vivo, IFN renders  NK cells selective for virus-infected target  cells by acting 
both at the effector and at the target cell levels. Our present data indicate that 
an  accessory HLA-DR  + cell able to produce  IFN-a  and  distinct  from effector 
NK cells plays an important role in regulating the ability of the NK cells to lyse 
CMV-infected targets,  and  thus  may contribute  to resistance  to infection  with 
this virus. 
Summary 
The role of HLA-DR  + cells in NK activity against CMV-infected FS4 foreskin 
fibroblasts and  K562 erythroleukemia  cells was examined.  When nonadherent 
PBMC were depleted of either  HLA-DR  + or  Leu-I lb  + cells by treatment  with 
mAbs plus C, NK activity against CMV-FS4 target cells was markedly reduced. 
In  contrast,  depletion  of HLA-DR  ÷ cells had  no effect on  NK activity against 
K562 target cells. When HLA-DR-depleted cells were added to Leu-11 b-depleted 
cells, NK activity against CMV-FS4 was restored. Negative selection experiments 
indicated that the HLA-DR  + cells contributing to NK activity against CMV-FS4 
are not B or T  cells, while negative and positive selection experiments excluded 
a role for monocytes. Experiments in which HLA-DR- and Leu-1 lb- cells were 
mixed in varying proportions indicated that NK(CMV-FS4) is mediated by Leu- 
11 b + cells, while HLA-DR  + cells provide an accessory function.  Irradiation  (50 
GY) abolished the NK effector function of Leu-11 b + cells, but not the accessory BANDYOPADHYAY ET  AL.  193 
function  of HLA-DR  +  cells.  The  NK  activity against  CMV-FS4  of HLA-DR- 
cells was restored by the addition ofrIFN-a or of cell-free supernatants generated 
by coculturing  PBMC  or  Leu-1 lb-  cells  with  CMV-FS4.  The  ability  of these 
supernatants to restore NK activity of HLA-DR- cells was completely abrogated 
by the addition of neutralizing amounts of antibody to IFN-a. In related exper- 
iments, neutralization of IFN-o~ in NK assays had little or no effect on NK activity 
against  CMV-FS4,  suggesting  that  the  accessory  function  of  HLA-DR  +  cells 
might  be  mediated  by alternative  mechanisms  in  addition  to  the  secretion  of 
extracellular IFN-a. 
Received for publication  30 December 1985 and in revised form 20 March 1986. 
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